Virtual Library

Start Your Search

A. Hata



Author of

  • +

    Poster Display session (Friday) (ID 65)

    • Event: ELCC 2018
    • Type: Poster Display session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 4/13/2018, 12:30 - 13:00, Hall 1
    • +

      170P - A phase II trial of nab-paclitaxel and gemcitabine in patients with non-small cell lung cancer previously treated with platinum based chemotherapy (ID 346)

      12:30 - 13:00  |  Author(s): A. Hata

      • Abstract

      Background:
      Nab-Paclitaxel plus gemcitabine significantly improved overall survival, progression-free survival, and response rate in patients with metastatic pancreatic adenocarcinoma. Combination treatment increases intra-tumoral gemcitabine levels attributable to a decrease in the primary gemcitabine metabolizing enzyme, cytidine deaminase. Based on these data, we planned to assess the efficacy and safety of combination with nab-PTX + gemcitabine in patients with non-small-cell lung cancer (NSCLC) previously treated with platinum based chemotherapy.

      Methods:
      Patients with advanced NSCLC with progressive disease to platinum-based chemotherapy, ECOG performance status (PS) 0 or 1, and adequate kidney, liver and bone marrow function were eligible. Treatment consisted of nab-paclitaxel (100 mg/m[2]) + gemcitabine (1000 mg/m[2]) on days 1 and 8 of each 3-week cycle until progression disease or unacceptable toxicity. The primary endpoint was progression-free survival (PFS).

      Results:
      Of the 28 patients enrolled, 28 were evaluable for response and toxicity. The median age was 68 years (range 47–79), 23 male and 5 female. Histology subtypes were: adenocarcinoma 19 patients, squamous cell carcinoma 9 patients. Seventeen patients had ECOG PS 1 and 11 patients had PS 0. Twenty-four patients were 2[nd] line and 4 patients were 3[rd] line. The median number of cycles administered was 4(range 1–10). The overall response rate was 17.9%. The disease control rate was 67.9%. The median progression-free survival was 3.3 months (95% confidence interval [CI] = 1.6–4.7). Four patients (14.3%) had grade 3 anemia, 3 patients (10.7%) had grade 3 thrombocytopenia, 5 patients (17.9%) had grade 4 neutropenia. However, no patients developed febrile neutropenia. Remarkable non-hematologic toxicity was interstitial pneumonia with grade 3 in 4 patients (14.3%), neuropathy with grade 1 in 2 patients (7.1%) and infections with grade 3 in 2 patients (7.1%).

      Conclusions:
      The efficacy of nab-Paclitaxel in combination with gemcitabine in advanced second or third-line NSCLC patients was limited and the high onset of interstitial pneumonia was unacceptable.

      Clinical trial identification:


      Legal entity responsible for the study:
      Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine

      Funding:
      Has not received any funding

      Disclosure:
      All authors have declared no conflicts of interest.